UNITED THERAPEUTICS Corp
For the period ended Jun 30, 2026. Filed Aug 5, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2026 · Filed Aug 5, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 6. Exhibits
| Exhibit No. | Description |
| 3.1 | Restated Certificate of Incorporation of the Registrant, incorporated by reference to Exhibit 3.1 of the Registrant’s Current Report on Form 8-K filed October 1, 2021 |
| 3.2 | Eleventh Amended and Restated Bylaws of the Registrant, incorporated by reference to Exhibit 3.1 of the Registrant’s Current Report on Form 8-K filed January 22, 2026 |
| 4.1 | Reference is made to Exhibits 3.1 and 3.2 |
| 10.1† | United Therapeutics Corporation 2026 Stock Incentive Plan, incorporated by reference to Exhibit 10.1 to the Registrant’s Current Report on Form 8-K filed June 29, 2026 |
| 10.2*+ | Fifteenth Amendment to Wholesale Product Purchase Agreement, dated as of June 10, 2026, by and between Priority Healthcare Distribution, Inc., doing business as CuraScript SD Specialty Distribution, and the Registrant |
| 10.3*† | Form of Grant Notice and Standard Terms and Conditions for Non-Qualified Stock Options Granted to Employees (Time Vesting) |
| 10.4*† | Form of Grant Notice and Standard Terms and Conditions for Non-Qualified Stock Options Granted to Employees (Performance Vesting) |
| 10.5*† | Form of Grant Notice and Standard Terms and Conditions for Non-Qualified Stock Options Granted to Non-Employee Directors |
| 10.6*† | Form of Grant Notice and Standard Terms and Conditions for Restricted Stock Units Granted to Employees (Time Vesting) |
| 10.7*† | Form of Grant Notice and Standard Terms and Conditions for Restricted Stock Units Granted to Employees (Performance Vesting) |
| 10.8*† | Form of Grant Notice and Standard Terms and Conditions for Restricted Stock Units Granted to Non-Employee Directors |
| 31.1* | Certification of Principal Executive Officer pursuant to Rule 13a-14(a) of the Securities Exchange Act of 1934 |
| 31.2* | Certification of Principal Financial Officer pursuant to Rule 13a-14(a) of the Securities Exchange Act of 1934 |
| 32.1** | Certification of Principal Executive Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 |
| 32.2** | Certification of Principal Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 |
| 101* | The following financial information from our Quarterly Report on Form 10-Q for the quarter ended June 30, 2026, filed with the SEC on August 5, 2026, formatted in Inline Extensible Business Reporting Language (iXBRL): (1) our Consolidated Balance Sheets as of June 30, 2026 and December 31, 2025; (2) our Consolidated Statements of Operations for the three- and six-month periods ended June 30, 2026 and 2025; (3) our Consolidated Statements of Comprehensive Income for the three- and six-month periods ended June 30, 2026 and 2025; (4) our Consolidated Statements of Stockholders’ Equity for the three- and six-month periods ended June 30, 2026 and 2025; (5) our Consolidated Statements of Cash Flows for the six-month periods ended June 30, 2026 and 2025; and (6) the Notes to our Consolidated Financial Statements. |
| 104* | Cover Page Interactive Data File (embedded within the iXBRL document) |
- Certain identified information has been omitted from this exhibit because it is both (1) not material; and (2) is the type that the registrant treats as private or confidential.
† Designates management contracts and compensation plans.
- Filed herewith.
** Furnished herewith.
Note: Except as otherwise noted above, all exhibits incorporated by reference to the Registrant’s previously filed reports with the Securities and Exchange Commission are filed under File No. 000-26301.
| 58 | United Therapeutics, a public benefit corporation |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.